Review
Open access
Sep 2026
Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer.
BACKGROUND The BRAF V600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis when treated with conventional chemotherapy regimens. Recent advances in research have shown promise in using combined BRAF inhibitor and an EGFR inhibitor to treat BRAF V600E-mutated mCRC, with international g...
Simar Gill, Ned Liu, Elaine Ngan et al.
· Clinical colorectal cancer · 0 citations